The effect of PHR spray on patients with coronavirus-19

ABSTRACT

ConditionCOVID-19.
U07.2COVID-19, virus not identified, COVID-19;U07.2

InterventionIntervention 1 Intervention groupThe group uses the following herbal medicine in addition to the current medicine for Covid-19 Drug Name Pinene-Hydronoplactone-Ribonucleoic-Abbreviation PHR160 - Drug Form Inhaler Spray --- Ingredients Sineol Menthol Crocin Safranol Alpha Tojun Oleic Acid Linoleic Acid Linolenic AcidIt was extracted from natural products found in 7 plant species by steam distillation method. These herbs have previously had a single, double or triple human consumption history. Effectives per puff 160 micrograms How to use PHR160 Determine the dosage approach for the above product based on the following 1. Due to the volume of the nozzle output and pump MDIs and the presence of propylant (HFA gas) and alcohol in the product concentration of essential oils and herbal compounds in the total MDI is about 0.3%. Therefore, the total amount of soluble natural substances available per puff is less than 300 nL or 270 mg, which, of course, reaches a limited proportion in the lungs. 1-20 g / kg of human body weight and these compounds are considered very safe and high dosage is much lower than the toxic range indicated and is 1/100 toxic in the case of essential oils.3. Products available on the market such as Eucalyptus Barrage incense, Eucalyptus dyne incense Pulmonary doses of essential oils are similar to our product compounds in excess of 30mg. Of the amount in each puff investigated product is less than 1/100 of the amount above 0.4. External products mainly used in Aroma Therapy Ascents, MBC Aerosol, Primatene Mist are examples of those with higher doses of essential oil.5.Refruitment time to discuss the use or inhalation of the above product 30-45 In this case, the maximum time interval of 1 hour of awakening has been suggested for this product to

Primary outcome:Measurement of cough severity. Timepoint Day 1 before and at the end of treatment. Method of measurement Standard cough questionnaire.;Severity of shortness of breath. Timepoint Day 1 before and at the end of treatment. Method of measurement Shortness Of Breath With Daily Activity (SOBDA) Questionnaire.;Lung radiologic changes. Timepoint At beginning and end of the study. Method of measurement Chest CT scan.

CriteriaInclusion criteria Male or female patients 18-65 years with COVID-19 confirmed by PCR (with mild involvement) - Ground glass view on CT scan - Arterial oxygen saturation less than 93% - Breathing more than 24 times per minute - At the Beginning onset of the disease - Negative pregnancy test in women - Completion of informed consent form by patient or supervisor

Exclusion criteria Oral ulcer or malignancy - history of pulmonary malignancy - history of asthma or COPD